UBS AM
DMRA

UBS AM’s Damora Therapeutics DMRA Stock Holding History

UBS AM’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$568K Buy
+21,838
New +$529K ﹤0.01% 2511

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

UBS AM's DMRA Position: Q2 2026 in Review

UBS AM opened a new position in Damora Therapeutics (DMRA) in Q2 2026: 21,838 shares worth $568K. The stake represents ﹤0.01% of the portfolio and ranks #2511 among its holdings.

104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • UBS AM held 21,838 shares of Damora Therapeutics worth $568K as of Q2 2026.
  • Damora Therapeutics was a new UBS AM position in Q2 2026.
  • Damora Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2511 holding.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.